Clinical Trials Directory

Trials / Completed

CompletedNCT00792909

Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A

Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
172 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
36 Months – 46 Months
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the immune memory induced by primary and booster vaccination with pneumococcal conjugate vaccine GSK1024850A in the first year of life through evaluation of the immune responses following vaccination with a booster dose of pneumococcal conjugate vaccine GSK1024850A in the fourth year of life and to assess immune responses following vaccination with a single dose of pneumococcal conjugate vaccine GSK1024850A in age-matched unprimed children. The study also aims to assess the antibody persistence in the fourth year of life following primary and booster vaccination with pneumococcal conjugate vaccine GSK1024850A in the first year of life. The study is also designed to evaluate the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following a 2-dose vaccination with pneumococcal conjugate vaccine GSK1024850A in the fourth year of life. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307034)

Conditions

Interventions

TypeNameDescription
BIOLOGICALPneumococcal conjugate vaccine GSK1024850AIntramuscular injection, 1 dose
BIOLOGICALPneumococcal conjugate vaccine GSK1024850AIntramuscular injection, 2 doses

Timeline

Start date
2008-12-02
Primary completion
2009-07-02
Completion
2009-07-02
First posted
2008-11-18
Last updated
2017-12-14
Results posted
2017-12-14

Locations

5 sites across 2 countries: Slovakia, Sweden

Source: ClinicalTrials.gov record NCT00792909. Inclusion in this directory is not an endorsement.